LIDEFARMA
ActiveSummary
LIDEFARMA has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €315,147 and a net result of €62,177. Equity is growing by about 7% per year across the filed financial years. Its solvency ranks better than 75% of 21,956 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
25-08
NBB filing
Annual accounts filed
financial year 2025 · micro format · 25 days late
2025
31-12
Financial
Highest result from 2018 to 2025net €62,177 ▲140%
Operating result €99,503, net result €62,177, both a record.
31-07
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
11-08
NBB filing
Annual accounts filed
financial year 2023 · micro format · 11 days late
2023
30-08
NBB filing
Annual accounts filed
financial year 2022 · micro format · 30 days late
2022
05-07
NBB filing
Annual accounts filed
financial year 2021 · micro format
2021
20-08
NBB filing
Annual accounts filed
financial year 2020 · micro format · 20 days late
2020
28-08
NBB filing
Annual accounts filed
financial year 2019 · micro format · 28 days late
2019
31-12
Financial
Equity above €200,000equity €204,581 ▲4.3%
A profit in every financial year since 2018 builds equity to €204,581.
28-08
NBB filing
Annual accounts filed
financial year 2018 · micro format · 28 days late
2018
23-07
NBB filing
Annual accounts filed
financial year 2017 · abbreviated format
2017
07-07
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 17 annual accounts filed, the latest 10 are here; all are under Financials.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.